A 6.75-kilobase human hepatoma-derived basic fibroblast growth factor (bFGF) cDNA was cloned and sequenced. An amino-terminal sequence generated from a purified hepatoma bFGF was found to correspond to the nucleotide sequence and to begin 8 amino acids upstream from the putative methionine start codon thought to initiate a 154-amino acid bFGF translation product. This sequence suggests that a form of bFGF of at least 163 amino acids exists. The hepatoma cDNA was transcribed in vitro into RNA; in vitro translation of this RNA generated three forms of bFGF with molecular masses of 18, 21, and 22.5 kDa. By use of in vitro mutagenesis, it was found that the 22.5-kDa bFGF and possibly the 21-kDa form were initiated with CUG start codons. The 18-kDa bFGF was initiated with an AUG codon. By transfecting into COS cells human hepatoma bFGF cDNA and a construct from which the AUG initiator was eliminated, it was found that the higher molecular mass forms of bFGF were as biologically active as the 18-kDa form.
biologically active as the 18-kDa form.
Basic fibroblast growth factor (bFGF) is a potent mitogen that stimulates growth and differentiation of a broad spectrum of mesodermal and neuro-ectodermal cell types (1) . The angiogenic activity of bFGF is related to the mitogenicity of this factor towards vascular endothelial cells (2, 3) . bFGF was originally purified from brain and pituitary as a 16-to 18-kDa monomeric polypeptide (4), but recently higher molecular mass bFGF forms of 25 kDa have been described (5) . A primary translation product of 154 amino acids has been predicted from the nucleotide sequence of bFGF cDNA (6) . However, a 157-amino acid placental bFGF has been described that includes at the amino-terminal end the methionine putatively claimed to be the bFGF start codon and 2 additional amino acids (7) . In addition, we report here that hepatoma cells produce a 163-amino acid form of bFGF that extends even beyond the amino terminus of the placental bFGF. ** These results are surprising because no AUG codon in frame has been found upstream of the putative start codon that is at the beginning of the bFGF open reading frame (ORF). However, we have cloned a hepatoma bFGF cDNA larger than previously reported (6, 8) . The 5'-end sequence of the hepatoma bFGF cDNA extends 466 nucleotides upstream of the putative methionine start codon. This leader sequence does not contain any AUG codons in frame with the bFGF nucleotide sequence but does contain several putative unusual start codons. Recently, the presence of an alternative CUG start codon able to initiate c-myc-1 protein as well as a viral protein were reported (9, 10) . In the article we report that a 22.5-kDa high molecular mass form of hepatomaderived bFGF is initiated with a CUG start codon.
MATERIALS AND METHODS
Cloning of the Human bFGF cDNA. Poly(A)+ RNA was prepared from human hepatoma cell line SK-HEP-1 as described by Cathala et al. (11) . A cDNA library was constructed by using a pUC9 vector as described by Caput et al. (12) and consisted of about 106 recombinant bacteria. Synthetic oligonucleotide probes based on the coding sequence ofthe bFGF were used to screen the library by in situ colony hybridization.
Amino Acid Sequence Analysis. bFGF was purified from an extract of hepatoma cells as described (13) by a combination of Bio-Rex 70 (Bio-Rad) chromatography, heparin chromatography, and HPLC reverse-phase chromatography with a C3 column and was analyzed with an Applied Biosystems 470A sequenator (13) .
DNA Sequence Analysis. The DNA sequencing was performed by the dideoxy chain-termination method (14) using restriction fragments cloned in M13mpl8 and M13mpl9 (Pharmacia).
In Vitro Mutagenesis and Plasmid Constructions. Point mutations on bFGF cDNA at positions 440 and 467 changing GGA to TGA and ATG to GTG, respectively, were generated by oligonucleotide-directed mutagenesis (15 GCAnAAGAGAGAGGAGTTGTGTCTATCnAA GGAGTGTGTGCTAACCGTTACCTGGCTATG AIaGluGluArgGIyVaeIVISerIleLys GlyValCysAlaAsnArgTyrLeuAlaMet TTTTAATGGCCACATCTAATCTCATTTCAC ATGAAAGAAGAAGTATATTTTAGAAATTTG  TTAATGAGAGTAAAAGAAAATAAATGTGTA TAGCTCAGTTTGGATAATTGGTCAAACAAT  TTTTTATCCAGTAGTAAAATATGTAACCAT TGTCCCAGTAAAGAAAAATAACAAAAGTTG  TAAAATGTATATTCTCCCTTTTATATTGCA TCTGCTGTTACCCAGTGAAGCTTACCTAGA  GCAATGATCTTTTTCACGCATTTGCTTTAT TCGAAAAGAGGCTTTTAAAATGTGCATGTT  TAGAAACAAAATTTCTTCATGGAAATCATA TACATTAGAAAATCACAGTCAGATGTTTAA  TCAATCCAAAATGTCCACTATTTCTTATGT CATTCGTTAGTCTACATGTTTCTAAACATA  TAAATGTGAATTTAATCAATTCCTTTCATA GTTTTATAATTCTCTGGCAGTTCCTTATGA  TAGAGTTTATAAAACAGTCCTGTGTAAACT GCTGGAAGTTCTTCCACAGTCAGGTCAATT  TTGTCAAACCCTTCTCTGTACCCATACAGC AGCAGCCTAGCAACTCTGCTGGTGATGGGA  GTTGTATTTTCAGTCTTCGCCAGGTCATTG AGATCCATCCACTCACATCTTAAGCATTCT  TCCTGGCAAAAATTTATGGTGAATGAATAT GGCTTTAGGCGGCAGATQATATACATATCT  GACTTCCCAAAAGCTCCAGGATTTGTGTGC TGTTGCCGAATACTCAGGACGGACCTGAAT  TCTGATTTTATACCAGTCTCTTCAAAAACT TCTCGAACCGCTGTGTCTCCTACGTAAAAA  AAGAGATGTACAAATCAATAATAATTACAC TTTTAGAAACTGTATCATCAAAGATTTTCA  GTTAAAGTAGCATTATGTAAAGGCTCAAAA CATTACCCTAACAAAGTAAAGTTTTCAATA  CAAATTCTTTGCCTTGTGGATATCAAGAAA TCCCAAAATATTTTCTTACCACTGTAAATT  CAAGAAGCTTTTGAAATGCTGAATATTTCT TTGGCTGCTACTTGGAGGCTTATCTACCTG   TACATTTTTGGGGTCAGCTCTTTTTAACTT CTTGCTGCTCTTTTTCCCAAAAGGTAAAAA  TATAGATTGAAAAGTTAAAACATTTTGCAT GGCTGCAGTTCCTTTGTTTCTTGAGATAAG  ATTCCAAAGAACTTAGATTCATTTCTTCAA CACCGAAATGCTGGAGGTGTTTGATCAGTT  TTCAAGAAACTTGGAATATAAATAATTTTA TAATTCAACAAAGGTTTTCACATTTTATAA  GGTTGATTTTTCAATTAAATGCAAATTTGT GTGGCAGGATTTTTATTGCCATTAACATAT  TTTTGTGGCTGCTTTTTCTACACATCCAGA TGGTCCCTCTAACTGGGCTTTCTCTAATTT  TGTGATGTTCTGTCATTGTCTCCCAAAGTA TTTAGGAGAAGCCCTTTAAAAAGCTGCCTT  CCTCTACCACTTTGCTGGAAAGCTTCACAA TTGTCACAGACAAAGATTTTTGTTCCAATA  CTCGTTTTGCCTCTATTTTTCTTGTTTGTC (Fig. 2) . N-Terminal Sequencing Analysis. Most of the bFGF purified from the hepatoma" cell line was amino-terminally blocked (13) . However, a small portion of the hepatoma bFGF sample had a free amino-terminal group available for Edman degradation, and the sequence of the 20-amino acid N-terminal protein fragment was obtained (Fig. 2) . The hepatoma bFGF amino-terminal sequence was compared with the amino-terminal sequence of human placenta bFGF (7) and with the sequence of the primary translation products of bFGF predicted from both the nucleotide sequence of hepatoma bFGF cDNA and the nucleotide sequence of bovine bFGF cDNA (19) . It is clear that the hepatoma bFGF fragment overlaps with the beginning of the bFGF ORF and extends 8 more amino acids upstream of the putative methionine start codon; 18 of the 20 amino acids in the hepatoma bFGF sequence are identical to those predicted from human hepatoma cDNA. Only the first 2 amino acids (-7 and -8) differ from the predicted sequence, but the identification of these 2 amino acids was tenuous. The first 2 amino acids (threonine at -1 and glycine at -2) of the hepatoma bFGF N-terminal extension corresponded to, and thus confirmed, the 2-amino acid N-terminal extension previously reported for placental bFGF (7) (Fig. 2) . Thus, there is strong evidence that hepatoma cells synthesize a form of bFGF that is larger than that predicted by the putative ORF and that the identification of the actual human bFGF ORF (6) Fig. 1 for comparison with the structural bFGF amino acid sequence shown in lines 1 and 2; the fourth line is a corresponding amino acid sequence for bovine brain bFGF deduced from bovine bFGF cDNA (19 (Fig. 3, lane 3) . Introduction of a TGA stop codon just upstream of ATG at 467 and in frame abolishes both the 21-and 22.5-kDa bFGF forms but not the 18-kDa form (Fig. 3, lane 4) . Thus, 21 (Fig. 3, lane 5) . On the other hand, replacement of CTG at 302 by ATG resulted in a dramatic 100-fold increase in synthesis of the 22.5-kDa bFGF (Fig. 3, lane 6) .
In Vivo Expression of bFGF cDNA. To find out if the higher molecular mass forms of bFGF are biologically active, bFGF cDNA and bFGF cDNA with the ATG codon at 467 replaced by GTG were transfected into monkey COS cells. COS cell extracts were tested for the ability to stimulate ABAE cell proliferation (Fig. 4) (13, 21, 22) and the nucleotide sequence of bFGF cDNA (6, 8) (9, 10) . We have cloned a hepatoma bFGF cDNA with a larger 5' extension and a slightly different sequence than has been reported previously (6, 8 stream of the AUG start codon. The evidence that the CUG codon at 302 initiates synthesis of 22.5-kDa bFGF is that alteration of this codon to UUG virtually eliminates synthesis of the high molecular mass form of bFGF. There is also some circumstantial evidence that the CUG codon at 344 might initiate synthesis of 21-kDa bFGF because initiation at this site would give bFGF of the predicted size and because CUG at 344 interestingly has a repeat of the region around the codon CUG at 302 (GAGG/CTG/GGGG, Fig. 3B ). Our in vitro translation studies indicate that initiation at unusual CUG start codons explains the existence of higher molecular mass forms of bFGF. However, hepatoma cells in culture appear to produce predominantly the 18-kDa form of bFGF (13) . In fact, almost all cells and tissue produce 18-kDa or even lower molecular mass forms of bFGF. One likely explanation is that protease-mediated truncation of bFGF occurs either posttranslationally or during bFGF extraction. We have found (21) that hepatoma cells contain acidactivated proteases that cleave bFGF at the N-terminal end. In addition, our experiments do not rule out the possibility that even higher molecular mass forms of bFGF exist, since it is not certain that the bFGF cDNA used to express bFGF is full length. Finally, although initiation at CUG codons is one possible mechanism for generating high molecular mass bFGF, other mechanisms such as alternative splicing might exist as well.
The efficiency of in vitro translation at the three initiation sites is low compared with that obtained when using globin mRNA. However, replacement of CUG at 302 with an AUG enhances by about 100-fold the synthesis of 22.5-kDa bFGF and also abolishes synthesis of the two lower mass forms of bFGF, suggesting (i) that CUG is less efficient than AUG as an initiation codon, as has been previously reported (23) , and (ii) that the low efficiency of the first start site scanned by nbosomes might favor the initiation of protein synthesis at other potential start sites, which is in agreement with the Kozak's model (24) . Therefore, we hypothesize than unusual start codons might be a means for down-regulation of protein synthesis as well as an important feature of alternative initiation of protein synthesis.
The size and initiation site of bFGF do not seem to affect its biological activity. In transfection experiments, the 22.5-kDa bFGF initiated at the CUG codon at position 302 is as mitogenic as the 18-kDa bFGF initiated at the AUG codon at 467. Hepatoma cells produce mostly 18-kDa bFGF (13) , but this molecular mass form could be a result of cell-mediated proteolysis of bFGF, which has been shown to occur in hepatoma cells (21) . Higher molecular mass forms are more prominent in tissues such as brain (5) 
